Search results for "Asthenia"

showing 10 items of 65 documents

The prevalence of post-thyroidectomy chronic asthenia: a prospective cohort study

2017

Chronic asthenia (CA) is complained by some patients that have undergone thyroid surgery. We evaluate its impact in patients undergoing unilateral or bilateral thyroidectomy, the trend during a 1-year follow-up, and the possible risk factors. A prospective, cohort study was carried out on 263 patients scheduled for thyroidectomy from 2012 and 2014. Exclusion criteria were as follows: Graves’ disease, malignancies requiring radioiodine therapy, post-surgical hypoparathyroidism, laryngeal nerve palsy, abnormal pre- and post-operative thyroid hormone levels, and BMI outside the normal range. Demographics; smoking and alcoholism addiction; cardiac, pulmonary, renal, and hepatic failure; diabete…

AdultMalemedicine.medical_specialtymedicine.medical_treatment030209 endocrinology & metabolismCohort Studies03 medical and health sciencesPostoperative Complications0302 clinical medicineRisk FactorsInternal medicineHemithyroidectomyPrevalencemedicineHumansRisk factorTotal thyroidectomyProspective cohort studyFatigueDepression (differential diagnoses)AgedChronic astheniabusiness.industryThyroidectomyMiddle Agedmedicine.diseaseThyroid DiseasesSurgeryCardiac surgerySettore MED/18 - Chirurgia GeneraleTreatment OutcomeHypoparathyroidismAsthenia030220 oncology & carcinogenesisChronic DiseaseThyroidectomyFemaleSurgerybusinessAbdominal surgeryCohort studyChronic asthenia; Fatigue; Hemithyroidectomy; Total thyroidectomy; Surgery
researchProduct

Immunosuppressive treatment of rippling muscles in patients with myasthenia gravis

2000

Rippling muscle disease is a rare autosomal dominant disorder that may occur sporadically. In this report two patients presenting with rippling muscles followed by myasthenia gravis are described. Our first patient developed rippling muscles about 1 month after infection with Yersinia enterocolitica. Two years later myasthenia gravis appeared. Our second patient had a 2-year history of asthma prior to the onset of rippling muscles which preceded the myasthenic symptoms by 4-8 weeks. Acetylcholine receptor and anti-skeletal muscle antibody titers were positive in both patients. In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosu…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAzathioprineGastroenterologyMuscular DiseasesPhysical StimulationInternal medicineAzathioprineMyasthenia GravismedicineHumansGenetics (clinical)AsthmaAcetylcholine receptorbusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseMyasthenia gravisNeurologyPyridostigmineRipplingPediatrics Perinatology and Child HealthImmunologyNeurology (clinical)medicine.symptombusinessImmunosuppressive AgentsMuscle ContractionPyridostigmine BromideMuscle contractionmedicine.drugNeuromuscular Disorders
researchProduct

Myasthenia gravis associated with Charcot-Marie-Tooth neuropathy: report of a case

1992

We report the case of a 24 year old woman who developed myasthenia gravis in the course of a mild form of Charcot-Marie-Tooth neuropathy. We describe the clinical manifestations together with the neurophysiological, pathological, serological findings and response to therapy and discuss the unusual association in the light of the relevant literature. © 1992 Masson Italia Periodici S.r.l.

Adultmedicine.medical_specialtyNeurologyResponse to therapySural nerve biopsySural NerveCharcot-Marie-Tooth DiseaseMyasthenia GravismedicineHumansReceptors CholinergicMild formPathologicalsural nerve biopsyNeuroscience (all)business.industryGeneral Neuroscienceanti-acetylcholine receptor antibodiemedicine.diseaseDermatologymyasthenia graviMyasthenia gravisSurgeryFemaleSettore MED/26 - NeurologiaNeurosurgeryNeurology (clinical)businessCharcot-Marie-Tooth neuropathy
researchProduct

Identifying human platelet glycoproteins IIb and IIIa by capillary electrophoresis.

1998

Glanzmann thrombasthenia (GT) is an inherited hemorrhagic defect due to a failure of the platelet membrane glycoprotein (GP) IIb–IIIa complex. Capillary electrophoresis (CE) analysis of solubilized platelet membranes from normal individuals showed the presence of two peaks with a migration time of 27 and 29 min, respectively. An excellent run-to-run and day-to-day reproducibility of the technique (< 1% variation of the retention time) was documented. Using an automated Ferguson method, the apparent molecular masses were 100.0 kDa and 138.5 kDa, respectively. Immunoprecipitation with monoclonal antibodies anti-GP IIIa (B59.2.1) and anti-IIb (61.9.1.3) showed the two peaks as IIIa and IIb, re…

Blood PlateletsMaleClinical BiochemistryPlatelet Glycoprotein GPIIb-IIIa ComplexPlatelet membrane glycoproteinBiochemistryAnalytical ChemistryCapillary electrophoresisThrombastheniamedicineHumansPlateletChildPolyacrylamide gel electrophoresischemistry.chemical_classificationMembrane GlycoproteinsGlanzmann's thrombastheniaCell MembraneElectrophoresis Capillarymedicine.diseaseFlow CytometryMolecular biologyPrecipitin TestsPlatelet Glycoprotein GPIIb-IIIa ComplexchemistryGlycoproteinThrombastheniaElectrophoresis
researchProduct

Sleep disordered breathing in medically stable patients with myasthenia gravis

2007

We investigate sleep and breathing in clinically stable myasthenia gravis (MG) patients and ask weather sleep disordered breathing (SDB) is causally linked with MG. Nineteen MG patients with a mean disease duration of 9.7 years underwent sleep studies in two consecutive nights. The primary outcome measure was the respiratory disturbance index (RDI) in terms of snoring and apneas/hypopneas. Further outcome measurements were total sleep time, sleep stage distribution and the number of arousals. A clinically relevant SDB in terms of obstructive sleep apnea (OSA) (defined as RDI > 10/h) was found in four patients. There were only a few central apneas (central apnea index: 0.19 +/- 0.4/h). We di…

Central sleep apneabusiness.industryCentral apneaSleep apneamedicine.diseaseSleep in non-human animalsMyasthenia gravisnervous system diseasesrespiratory tract diseasesObstructive sleep apneaNeurologySleep and breathingAnesthesiaRespiratory disturbance indexMedicineNeurology (clinical)businessEuropean Journal of Neurology
researchProduct

Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis

2022

Von Hippel-Lindau (VHL) disease is an autosomal dominant condition that predisposes affected individuals to a variety of malignant and benign neoplasms. The pathogenetic turning point of this illness is the accumulation of hypoxia-inducible factor (HIF)-1α, a transcription factor of several genes involved in oncogenesis, angiogenesis, tissue regeneration, metabolic regulation, hematopoiesis, and inflammatory responses. From an oncological perspective, increased awareness of the molecular pathways underlying this disease is bringing us closer to the development of specific and targeted therapies. Meanwhile, on the surgical side, improved understanding can help to better identify the patients…

Clinical BiochemistryAch receptors VHL disease VHL/HIF axis belzutifan immune system myasthenia gravis inflammation pazopanib
researchProduct

Low Levels of Acetylcholine Receptor Delta-Subunit Message and Protein in Human Thymus Suggests the Occurrence of ‘Triplet Receptors’ in Thymic Myoid…

2000

Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction [1]. The muscular AChR has been extensively characterized [2], but whether the muscular AChR plays a role during the initiation of MG is unknown [3]. The muscular AChR is a pentameric ion channel composed of 4 different subunits [2, 4]. The fetal AChR expressed during intrauterine life and after denervation of adult muscle exhibits an α2βδγ composition, while the adult AChR expressed after birth in innervated muscle exhibits an α2βδγ composition [4]. The α-subunit contains the main epitopes recognized by MG autoantibodies [2]. The human muscle AChR…

DenervationGene isoformmedicine.medical_specialtyanimal structuresThymomaBiologymusculoskeletal systemmedicine.diseaseMolecular biologyEpitopeMyasthenia gravisNeuromuscular junctionEndocrinologymedicine.anatomical_structureInternal medicinemedicineReceptortissuesAcetylcholine receptor
researchProduct

Alternatively spliced transcripts of the thymus-specific protease PRSS16 are differentially expressed in human thymus.

2004

The putative serine protease PRSS16 is abundantly expressed in the thymic cortex and the gene is encoded within the HLA I complex. Although its function is not yet defined, the very restricted expression points to a role in T-cell development in the thymus. In this study, we show that the PRSS16 mRNA is alternatively spliced to generate at least five transcripts. Apart from the full-length sequence, we found two other isoforms with all putative active site residues of the serine protease, suggesting that those variants may also be functional. Semi-quantitative analysis of the splice variants in different tissue samples revealed a strong correlation between the specific formation of alternat…

Gene isoformAdultMaleThymomamedicine.medical_treatmentImmunologyMolecular Sequence DataMorphogenesisThymus GlandGene Expression Regulation EnzymologicMyasthenia GravisGeneticsmedicineMorphogenesisHumansGeneGenetics (clinical)Serine proteaseMessenger RNAProteasebiologyBase SequenceSerine EndopeptidasesMiddle Agedmedicine.diseaseMolecular biologyMyasthenia gravisIsoenzymesAlternative Splicingbiology.proteinFemaleGenes and immunity
researchProduct

Expression of the Acetylcholine Receptor α-Subunit Gene is Associated with Paraneoplastic Myasthenia Gravis in Mixed Thymoma

2000

Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction [1]. The muscular AChR has been extensively characterized [2], but the etiology of MG is still obscure. Whether the muscular AChR or another (auto)antigen plays a role during the initiation of MG is unknown [3]. The muscular AChR is a pentameric ion channel composed of four different subunits. The α-subunit contains the acetylcholine binding site and the main epitopes recognized by MG autoantibodies [2]. The human muscle AChR α-subunit exists as two isoforms, P3A- and P3A+ [4]. This is a result of alternative splicing of the P3A exon located betwee…

Gene isoformanimal structuresChemistryAlternative splicingmusculoskeletal systemmedicine.diseasemedicine.disease_causeMolecular biologyNeuromuscular junctionMyasthenia gravisAcetylcholine bindingMolecular mimicrymedicine.anatomical_structureNicotinic agonistmedicinetissuesAcetylcholine receptor
researchProduct

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohor…

2015

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the i…

Genetics and Molecular Biology (all)MaleChronic HepatitisHepacivirusRibavirin/adverse effectsAsthenia/chemically inducedHepacivirusPolyethylene GlycolBiochemistryPolyethylene GlycolsBody Mass IndexChronic Liver Disease0302 clinical medicineNeutropenia/chemically inducedInterferon-alpha/adverse effectsMedicineChroniclcsh:ScienceLiver Diseasesvirus diseasesAntiviral Agents/adverse effectsCohortScience & Technology - Other Topics030211 gastroenterology & hepatologyDrug Therapy CombinationCohort studyHumanmedicine.medical_specialtyAlpha interferonGastroenterology and HepatologyAntiviral AgentsMicrobiologyDose-Response Relationship03 medical and health sciencesPharmacotherapyHepatitis C Chronic/drug therapyDose Prediction MethodsDrug TherapyAnemia/chemically inducedHumansHemoglobinAgedMedicine and health sciencesBiochemistry Genetics and Molecular Biology (all)HepaciviruScience & TechnologyDose-Response Relationship DrugFlaviviruseslcsh:ROrganismsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseaseschemistryAgricultural and Biological Sciences (all)Withholding TreatmentAstheniaImmunologyProportional Hazards Modellcsh:QHuman medicineRNA virusesPhysiologylcsh:MedicinePeginterferon-alfaPolyethylene Glycols/adverse effectsAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Cohort Studieschemistry.chemical_compoundOutcome Assessment Health CareMedicine and Health Sciences030212 general & internal medicineViralPathology and laboratory medicineMultidisciplinarybiologyHepatitis C virusPharmaceuticsMedicine (all)AnemiaHepatitis CHematologyRecombinant ProteinOutcome Assessment (Health Care)/methodsMiddle AgedMedical microbiologyHepatitis CRecombinant ProteinsHost-Pathogen InteractionMultidisciplinary SciencesPhysiological ParametersResearch DesignCombinationHost-Pathogen InteractionsVirusesRNA ViralFemaleDrugPathogensHost-Pathogen Interactions/drug effectsResearch ArticleAdultNeutropeniaClinical Research DesignResearch and Analysis MethodsOutcome Assessment (Health Care)Internal medicineRibavirinRecombinant Proteins/adverse effectsRNA Viral/bloodAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding TreatmentAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Medicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Proportional Hazards ModelsAntiviral Agentbusiness.industryRibavirinBody WeightHepacivirus/drug effectsViral pathogensInterferon-alphaHepatitis C Chronicbiology.organism_classificationHepatitis virusesMicrobial pathogensRNAAdverse EventsCohort StudiebusinessPloS one
researchProduct